EyeGate Pharmaceuticals Stock Forecast, Price & News

+0.10 (+5.26 %)
(As of 09/17/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume3.75 million shs
Average Volume1.62 million shs
Market Capitalization$25.24 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive EYEG News and Ratings via Email

Sign-up to receive the latest news and ratings for EyeGate Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

EyeGate Pharmaceuticals logo

About EyeGate Pharmaceuticals

EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.45 out of 5 stars

Medical Sector

136th out of 1,350 stocks

Pharmaceutical Preparations Industry

63rd out of 664 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

EyeGate Pharmaceuticals (NASDAQ:EYEG) Frequently Asked Questions

Is EyeGate Pharmaceuticals a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for EyeGate Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EyeGate Pharmaceuticals stock.
View analyst ratings for EyeGate Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than EyeGate Pharmaceuticals?

Wall Street analysts have given EyeGate Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but EyeGate Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting EyeGate Pharmaceuticals?

EyeGate Pharmaceuticals saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 81,500 shares, an increase of 49.5% from the August 15th total of 54,500 shares. Based on an average daily trading volume, of 1,780,000 shares, the days-to-cover ratio is presently 0.0 days.
View EyeGate Pharmaceuticals' Short Interest

When is EyeGate Pharmaceuticals' next earnings date?

EyeGate Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, November 8th 2021.
View our earnings forecast for EyeGate Pharmaceuticals

How were EyeGate Pharmaceuticals' earnings last quarter?

EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) issued its quarterly earnings data on Thursday, August, 12th. The specialty pharmaceutical company reported ($0.35) earnings per share for the quarter, topping analysts' consensus estimates of ($0.42) by $0.07.
View EyeGate Pharmaceuticals' earnings history

How has EyeGate Pharmaceuticals' stock been impacted by Coronavirus?

EyeGate Pharmaceuticals' stock was trading at $5.03 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, EYEG shares have decreased by 60.2% and is now trading at $2.00.
View which stocks have been most impacted by COVID-19

What price target have analysts set for EYEG?

2 equities research analysts have issued 12 month price objectives for EyeGate Pharmaceuticals' stock. Their forecasts range from $9.50 to $11.00. On average, they expect EyeGate Pharmaceuticals' share price to reach $10.25 in the next twelve months. This suggests a possible upside of 412.5% from the stock's current price.
View analysts' price targets for EyeGate Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are EyeGate Pharmaceuticals' key executives?

EyeGate Pharmaceuticals' management team includes the following people:
  • Brian Matthew Strem, President, Chief Executive Officer & Director
  • Sarah M. Romano, Chief Financial & Accounting Officer
  • Lisa Brandano, Vice President-Clinical Operations
  • Franz Obermayr, Executive Vice President-Clinical Development
  • Brenda K. Mann, Vice President-Research & Development

Who are some of EyeGate Pharmaceuticals' key competitors?

What other stocks do shareholders of EyeGate Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other EyeGate Pharmaceuticals investors own include Bausch Health Companies (BHC), MannKind (MNKD), Sorrento Therapeutics (SRNE), Idera Pharmaceuticals (IDRA), Celldex Therapeutics (CLDX), Novavax (NVAX), SCYNEXIS (SCYX), Trevena (TRVN), Exelixis (EXEL) and Gilead Sciences (GILD).

When did EyeGate Pharmaceuticals IPO?

(EYEG) raised $5 million in an initial public offering (IPO) on Friday, February 13th 2015. The company issued 800,000 shares at $6.00 per share. Aegis Capital Corp and Chardan Capital Markets acted as the underwriters for the IPO.

What is EyeGate Pharmaceuticals' stock symbol?

EyeGate Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYEG."

Who are EyeGate Pharmaceuticals' major shareholders?

EyeGate Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (1.80%) and Renaissance Technologies LLC (1.27%). Company insiders that own EyeGate Pharmaceuticals stock include Armistice Capital Master Fund, Armistice Capital, Llc and Morton Goldberg.
View institutional ownership trends for EyeGate Pharmaceuticals

Which major investors are selling EyeGate Pharmaceuticals stock?

EYEG stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.
View insider buying and selling activity for EyeGate Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying EyeGate Pharmaceuticals stock?

EYEG stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. Company insiders that have bought EyeGate Pharmaceuticals stock in the last two years include Armistice Capital Master Fund, and Armistice Capital, Llc.
View insider buying and selling activity for EyeGate Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of EyeGate Pharmaceuticals?

Shares of EYEG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is EyeGate Pharmaceuticals' stock price today?

One share of EYEG stock can currently be purchased for approximately $2.00.

How much money does EyeGate Pharmaceuticals make?

EyeGate Pharmaceuticals has a market capitalization of $25.24 million and generates $10,000.00 in revenue each year. The specialty pharmaceutical company earns $-8,090,000.00 in net income (profit) each year or ($1.77) on an earnings per share basis.

How many employees does EyeGate Pharmaceuticals have?

EyeGate Pharmaceuticals employs 14 workers across the globe.

What is EyeGate Pharmaceuticals' official website?

The official website for EyeGate Pharmaceuticals is

Where are EyeGate Pharmaceuticals' headquarters?

EyeGate Pharmaceuticals is headquartered at 271 WAVERLEY OAKS ROAD SUITE 108, WALTHAM MA, 02452.

How can I contact EyeGate Pharmaceuticals?

EyeGate Pharmaceuticals' mailing address is 271 WAVERLEY OAKS ROAD SUITE 108, WALTHAM MA, 02452. The specialty pharmaceutical company can be reached via phone at (781) 788-8869 or via email at [email protected].

This page was last updated on 9/19/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.